Sai Life Sciences has reported results for fourth quarter (Q4) and year ended March 31, 2025.
The company has reported 46.24% rise in its net profit at Rs 89.94 crore for the quarter under review as compared to Rs 61.50 crore for the same quarter in the previous year. The total income of the company increased by 33.61% at Rs 576.83 crore for Q4FY25 as compared Rs 431.73 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 57.26% rise in its net profit at Rs 88.27 crore for fourth quarter ended March 31, 2025 as compared to Rs 56.13 crore for the same quarter in the previous year. The total income of the company increased by 33.12% at Rs 589.11 crore for Q4FY25 as compared Rs 442.55 crore for the corresponding quarter previous year.
For the year ended March 31, 2025, the company has reported 82.15% rise in its net profit at Rs 173.46 crore as compared to Rs 95.23 crore for the previous year. The total income of the company increased by 15.98% at Rs 1,679.38 crore for year under review as compared to Rs 1,448.01 crore for year ended March 31, 2024.
For the year ended March 31, 2025, on the consolidated basis, the company has reported over two folds jump in its net profit at Rs 170.13 crore as compared to Rs 82.81 crore for the previous year. The total income of the company increased by 15.87% at Rs 1,731.35 crore for year under review as compared to Rs 1,494.27 crore for year ended March 31, 2024.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: